Member Info for Ghia

TLW - Precisely why so many have extreme confidence in the board. They release news when they have something important to say and they make damn right sure it’s factual and accurate.

No if, buts - U turns dodgy cash raises etc.

Only a few days of trading left before Xmas break not many shares available expect doom and gloom here this week to try and extract every last loose share at this price point.

Events are conspiring in favour of SNG by the minute. Just let it all unfold and try and get as many tickets to the show as possible.

Incorrect Andy

The true value here will come when orders are booked and product shipped.

Then the share price values itself. It may get ahead of itself due to demand and shortage of shares.

But quite simply the true value of the stock will be due to it’s balance sheet and order book. Valuing a stock on momentum, perception, tendency for fomo etc is how investors loose money.

More exposure and more retail investors = greater volatility

No thank you!!

You’ve just highlighted a stock that gained $5billion and then lost $3billion of its gains, that’s not a stock i want to be invested in.

Much happier with a slower pace with value built on substance.

SNG for me has been a share which I can happily drop feed into taking advantage of any lows and just sit patiently knowing that the Board have it under control it’s a dream investment.

LimaLiam - I wonder if he will make a comment for teh shareholders like last time.

last time it went something like

"all I can say to investors is watch our news we are a news driven company so I would say to invesators wait for our news"

Yet people still sold the friday before Manic Monday!

“ So far I do not know who the buyer is but will update when I find out. All I know is that there is a new buyer out there.”

What City means is when the person close to the source of the rumour posts more info on a closed forum that I watch I will post the rumour here and pass it off as my own information…

Matml74 - another thing that I believe the market has overlooked is the fact that SNG probably don’t need a major pharma partner to get this across the line.

The current state of play is very different to pre-pandemic times.

Pre pandemic your time to approval and cash burn to approval was high and once approved you’d have to actively market the drug, the links and networks that major pharma have would be essential.

The state of play now is that if you have a drug that is promising and has good data governments will place massive orders and forward fund manufacturing scale up.

Major pharma offer nothing to SNG currently which is why we have seen some interesting hirings around the manufacturing and supply chain governance.

I fully expect SNG to ship product for 12months before a major pharma is allowed in on the action at that pharma will be brought in to bankroll the future development of SNG as a broad spectrum and as a combination therapy.

Sold out of GDR a long time ago but nice to see today’s announcement for everyone involved. This is a very timely announcement as European the U.K. grapple with how to stay out of lockdowns and function. It’s test will be a useful tool to have in the fight.

Game On!!

He may have said in that video data by end of year but clearly in the latest RNS and subsequent pro active interview which post date this video Q1 2022 is clearly the target.

Let’s not get carried away.

Haha seems I have caused somewhat of a controversy!! Typo should have read £1.62 although if anyone wants to sell me at £1.52 I’ll bite their hand off.

Thanks to whoever sold me their shares earlier at £1.52 if you’ve got any more at that price please let me know.

Certainly worth having cash available to take advantage of global weakness.

I’ve been watching the Evergrande situation for months now ever since they pulled out of a business deal we had with them.

You can’t find any trial data on it because there has been no trials. They’ve identified a pathway in the lab and have proposed a drug that could be repurposed. Next step would be to trial this drug to prove it works.

The way I see it is our drug is stimulating a natural response in our body, which is strong in some and weaker in others.

If Covid or any other virus figured out how to evade effectively this natural IFN response we would all be in a lot of trouble.

What’s happening currently is those with a weaker response can get overwhelmed easily by the virus, those with a strong response fair reasonably well.

IV study is in the bag IMO.

Much better for the share to be traded on the way up and down it provides more support.

Andy - well done for sticking it out if you look back over your period invested whilst it may have been mighty frustrating I’m sure there will be periods where you where nicely in profit and other times where you where under water.

The lesson which I hope you take from this is that if you have invested in a well managed and reputable company, if the fundamentals behind the investment have not changed the price fluctuations are just that fluctuations.

There is normally always opportunities to get out with a profit and if you hold your nerve you can usually avoid making significant losses.

Patience is the key both when buying and selling.

Personally looking at the news hires I think the intention is to seek EUA and ship product before takeover.

We have armed ourselves with the capability to distribute product to market to at least service government stockpiling requirements.

The value of big pharma is managing the long term future of the product and broadening it’s use case, doing more complicated and niche trials looking at specific subsets of the population.

RM is not stupid I’m sure he will want to have some orders on the book to strengthen our negotiation position.

Doc - if Sprinter was still due to complete and file this year then maybe buy the sprinter delay has muted the share price. People now know the real action will happen in Q1 2022. Unless we bag a tasty pre-order off the back of Active progression.

But I believe this will require SNG to apply for EUA first and I don’t see that happening until after sprinter files.

Not sure why people are expecting more of a rise.

Progression is great but we don’t have any data to look at yet so we don’t know how strong the signal was.

It’s another welcome milestone but doesn’t make sprinter P3 complete any quicker.

Approvals and Orders are what will get this share price moving significantly.

Other news underpins the current price the delay news only saw a low of £1.2 where as previously that would have tested sub £1. We are building strong foundations but don’t expect a massive correction yet.

The real movement is likely to happen early next year.